Does the drug dapagliflozin benefit hospitalized patients with COVID-19?
In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin did not significantly reduce patients' risk ...
Apr 28, 2022
0
3